ATE451106T1 - Behandlung von sti571-resistenter oder - intoleranter chronischer myelogener leukemie mittels homoharringtonine alein oder in kombination mit anderen substanzen - Google Patents

Behandlung von sti571-resistenter oder - intoleranter chronischer myelogener leukemie mittels homoharringtonine alein oder in kombination mit anderen substanzen

Info

Publication number
ATE451106T1
ATE451106T1 AT02772653T AT02772653T ATE451106T1 AT E451106 T1 ATE451106 T1 AT E451106T1 AT 02772653 T AT02772653 T AT 02772653T AT 02772653 T AT02772653 T AT 02772653T AT E451106 T1 ATE451106 T1 AT E451106T1
Authority
AT
Austria
Prior art keywords
sti571
treatment
intolerant
substances
resistant
Prior art date
Application number
AT02772653T
Other languages
English (en)
Inventor
Jean-Pierre Robin
Francois-Xavier Mahon
Herve Maisonneuve
Frederick Maloisel
Julie Blanchard
Original Assignee
Chemgenex Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemgenex Pharmaceuticals Ltd filed Critical Chemgenex Pharmaceuticals Ltd
Application granted granted Critical
Publication of ATE451106T1 publication Critical patent/ATE451106T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT02772653T 2001-09-05 2002-09-05 Behandlung von sti571-resistenter oder - intoleranter chronischer myelogener leukemie mittels homoharringtonine alein oder in kombination mit anderen substanzen ATE451106T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31696701P 2001-09-05 2001-09-05
PCT/IB2002/003992 WO2003020252A2 (en) 2001-09-05 2002-09-05 Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents

Publications (1)

Publication Number Publication Date
ATE451106T1 true ATE451106T1 (de) 2009-12-15

Family

ID=23231501

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02772653T ATE451106T1 (de) 2001-09-05 2002-09-05 Behandlung von sti571-resistenter oder - intoleranter chronischer myelogener leukemie mittels homoharringtonine alein oder in kombination mit anderen substanzen
AT09172828T ATE548041T1 (de) 2001-09-05 2002-09-05 Homoharringtonine allein oder in kombination mit anderen substanzen zur anwendung zur behandlung von chronischer myelogenischer leukemia resistent oder intolerant gegenüber proteinkinasehemmern ausgenommen sti 571

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT09172828T ATE548041T1 (de) 2001-09-05 2002-09-05 Homoharringtonine allein oder in kombination mit anderen substanzen zur anwendung zur behandlung von chronischer myelogenischer leukemia resistent oder intolerant gegenüber proteinkinasehemmern ausgenommen sti 571

Country Status (12)

Country Link
US (1) US6987103B2 (de)
EP (2) EP1443933B1 (de)
JP (2) JP4794816B2 (de)
AT (2) ATE451106T1 (de)
AU (1) AU2002337410A1 (de)
CA (1) CA2459822C (de)
CY (2) CY1109799T1 (de)
DE (1) DE60234708D1 (de)
DK (2) DK1443933T3 (de)
ES (2) ES2383771T3 (de)
PT (2) PT1443933E (de)
WO (1) WO2003020252A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613753B2 (en) * 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
US6998391B2 (en) * 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
US20040192652A1 (en) * 2002-12-06 2004-09-30 Giles Francis J. Pharmaceutical combinations and methods for the treatment of leukemia
US20050037992A1 (en) * 2003-07-22 2005-02-17 John Lyons Composition and method for treating neurological disorders
US20050059682A1 (en) * 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
US7250416B2 (en) * 2005-03-11 2007-07-31 Supergen, Inc. Azacytosine analogs and derivatives
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
US20070117776A1 (en) * 2005-11-04 2007-05-24 John Lyons Low Dose Therapy Of DNA Methylation Inhibitors
BRPI0710496A2 (pt) * 2006-04-07 2011-08-16 Novartis Ag combinação que compreende a) composto de pirimidilaminobenzamida e b) inibidor de thr315iie cinase
EP2049096A4 (de) * 2006-08-02 2012-05-09 Univ South Florida Verfahren zur behandlung chronischer myelogener leukämiezellen
AU2008240044B2 (en) * 2007-04-13 2013-09-12 Teva Pharamceuticals International Gmbh Oral cephalotaxine dosage forms
EP2229160A1 (de) * 2007-12-07 2010-09-22 ChemGenex Pharmaceuticals, Inc. Ablation von leukämie-stammzellen
JP5617175B2 (ja) 2008-04-17 2014-11-05 富士電機株式会社 ワイドバンドギャップ半導体装置とその製造方法
CN103619168B (zh) * 2011-06-29 2015-09-23 宾州研究基金会 用于治疗白血病的组合物、方法和药盒
HUE042327T2 (hu) 2011-08-30 2019-06-28 Astex Pharmaceuticals Inc Decitabin-származék készítmények
WO2017004538A1 (en) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Lyophilized pharmaceutical compositions
BR112020002280A2 (pt) 2017-08-03 2020-07-28 Otsuka Pharmaceutical Co., Ltd. composto farmacológico e métodos purificação do mesmo

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030148955A1 (en) * 1999-04-19 2003-08-07 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders

Also Published As

Publication number Publication date
HK1067562A1 (en) 2005-04-15
US6987103B2 (en) 2006-01-17
EP2177223A3 (de) 2010-05-19
DK1443933T3 (da) 2010-01-25
HK1143732A1 (en) 2011-01-14
PT1443933E (pt) 2010-01-27
WO2003020252A2 (en) 2003-03-13
EP1443933A2 (de) 2004-08-11
EP1443933B1 (de) 2009-12-09
CY1109799T1 (el) 2014-09-10
EP2177223B9 (de) 2012-10-31
CA2459822C (en) 2013-01-29
CY1112817T1 (el) 2016-02-10
DK2177223T3 (da) 2012-04-10
PT2177223E (pt) 2012-05-23
JP2009102408A (ja) 2009-05-14
AU2002337410A1 (en) 2003-03-18
CA2459822A1 (en) 2003-03-13
EP2177223B1 (de) 2012-03-07
ES2334774T3 (es) 2010-03-16
DE60234708D1 (de) 2010-01-21
EP2177223A2 (de) 2010-04-21
ATE548041T1 (de) 2012-03-15
US20040019036A1 (en) 2004-01-29
ES2383771T3 (es) 2012-06-26
JP4794816B2 (ja) 2011-10-19
WO2003020252A3 (en) 2003-06-19
JP2005508896A (ja) 2005-04-07

Similar Documents

Publication Publication Date Title
CY1112817T1 (el) Ομοχαρριγκτονινη μονη ή συνδυασμενη με αλλους παραγοντες για χρηση στην αγωγη της χρονιας μυελογενους λευχαιμιας, ανθεκτικης ή μη ανεκτικης σε αναστολεις πρωτεϊνικης κινασης εκτος του sτi 571
DK1503788T3 (da) Behandling af alpha-galactosidase A-deficiens
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE60042598D1 (de) Medikamente zur behandlung des syndroms der chronishen ermüdung, das mit fibromyalgie und reizdarm assoziert ist.
ATE422358T1 (de) Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen
DE60115872D1 (de) Cabergolin zur behandlung von fibromyalgie und chronic-fatigue-syndrom
ATE361089T1 (de) Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin
DE602004005814D1 (de) Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
DE602004022285D1 (de) Verfahren zur behandlung von erkrankungen mit hsp90-hemmenden mitteln in kombination mit antimitotika
DE602004011051D1 (de) Verfahren zur behandlung von krankheiten mit hsp90-hemmenden mitteln in kombination mit antimetaboliten
DE602004017283D1 (de) Verfahren zur behandlung von schwerer herzinsuffizienz und medikament dafür
DE60330525D1 (de) Dynamische Anpassung einer Wegwerfschwelle zur fairen Behandlung von Multicast- und Unicastdatenrahmen
DE69833645D1 (de) Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen
ATE356994T1 (de) Screeningverfahren mit pim1-kinase oder pim3- kinase
DE60206289D1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
ATE356995T1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
DE602004004883D1 (de) Vegf-antagonisten zur behandlung von diabetes
ATE222101T1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
ATE427745T1 (de) Zusammensetzungen und verfahren zur erhíhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus
DE60128009D1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
DE602004016126D1 (de) Aplidine zur behandlung von multiplem myelom
DE60206280D1 (de) Verwendung von extrakten aus ginkgo biloba zur herstellung eines medikaments zur behandlung von sarcopenia
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
DE50308460D1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen
DE602006020838D1 (de) Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1443933

Country of ref document: EP